Brief: Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
04/12/2024 14:04
Dec 4 (Reuters) - Outlook Therapeutics Inc OTLK.O :
* OUTLOOK THERAPEUTICS® ANNOUNCES NICE RECOMMENDATION OF
LYTENAVA™
(BEVACIZUMAB GAMMA) FOR THE TREATMENT OF WET AMD
* OUTLOOK THERAPEUTICS INC - FIRST POSITIVE REIMBURSEMENT
DECISION
WORLDWIDE FOR LYTENAVA™; FIRST LAUNCH ANTICIPATED IN H1 2025
* OUTLOOK THERAPEUTICS INC - ENTERS STRATEGIC COLLABORATION
WITH
CENCORA
Source text: ID:nGNX5p3GRM
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce